Top Markets
#1 Cortex Cortex +32.97%
#2 DexNet DexNet +23.20%
#3 龙虾 (Lobster) 龙虾 (Lobster) +19.81%
#4 wojak wojak +17.68%
#5 Pons Pons +15.94%
#6 Akedo Akedo +13.13%
#7 MarsCoin MarsCoin +9.56%
#8 OpenEden OpenEden +9.38%
#9 EXOD EXOD +9.04%
#10 BNB Attestation Service BNB Attestation Service +8.85%
Coin of the day
Cortex Cortex
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Classifica tra le azioni #7320
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Prezzo delle azioni
$1.94
Capitalizzazione di mercato
$1.63B
Variazione (1 giorno)
-7.12%
Variazione (1 anno)
18.87%
Paese
CN
Scambia HBM Holdings Limited (2142)

Categoria

Healthcare
Ricavi di HBM Holdings Limited (2142)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di HBM Holdings Limited, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per HBM Holdings Limited da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH